Since IR is one of the major pathways in NAFLD, the appetite and satiety signals modulated by insulin could be impaired in these patients; most pharmacological treatments aim to improve IR and their linked comorbidities in NAFLD patients; therefore, with the improvement of IR, NAFLD and other metabolic markers could improve. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.